Nabriva (NBRV) Prices 6M Share Common Offering at $2.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 4% to two-week high after Trump says deal with Iran 'over'
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
December 10, 2020 11:18 PM ESTDUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the pricing of its public offering of 6,000,000 ordinary shares (or pre-funded warrants in lieu thereof) at an effective offering price to the public of $2.50 per share (or pre-funded warrant).
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Northland Securities, Inc. is acting as financial advisor in connection with the... More
